Yüklüyor......
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
Tyrosine Kinase Inhibitors (TKI) have significantly changed the landscape of current cancer therapy. Understanding of mechanisms of aberrant TK signaling and strategies to inhibit TKs in cancer, further promote the development of novel agents. ABT-869, a novel ATP-competitive receptor tyrosine kinas...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2009
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2729745/ https://ncbi.nlm.nih.gov/pubmed/19642998 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-2-33 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|